Alprostadil (Caverject/MUSE) and Diphenhydramine Interaction

How Alprostadil Works in the Body

Alprostadil is synthetic prostaglandin E1 (PGE1). After injection into the corpus cavernosum (Caverject) or insertion as a urethral suppository (MUSE), it binds EP2 and EP3 prostaglandin receptors on smooth-muscle cells, raises intracellular cyclic AMP (cAMP), and relaxes cavernosal smooth muscle to produce penile erection [1]. Systemic absorption is real but limited: intracavernosal alprostadil shows rapid local metabolism, with plasma half-life under 10 minutes [2]. MUSE delivers higher systemic exposure because urethral absorption bypasses local penile metabolism more readily.

Vasodilation and Blood Pressure

Even with the short half-life, alprostadil-induced vasodilation produces measurable blood-pressure drops. The FDA-approved Caverject prescribing information reports hypotension as a known adverse effect, occurring in up to 3% of patients in controlled trials, and instructs clinicians to have patients remain seated for at least 30 minutes after the first dose [1]. MUSE prescribing information similarly notes that 3% of men in key studies experienced dizziness consistent with hypotension [3].

Penile Pharmacokinetics

Local penile tissue metabolizes PGE1 to 15-keto-PGE1 and further to 13,14-dihydro-15-keto-PGE1. These metabolites are pharmacologically inactive. Hepatic first-pass clearance removes approximately 80% of any drug that reaches systemic circulation [2]. This rapid metabolism limits sustained systemic effects but does not eliminate the acute hypotensive window during and shortly after dosing.

How Diphenhydramine Works and Why It Matters Here

Diphenhydramine is a first-generation H1-receptor inverse agonist. It crosses the blood-brain barrier freely, producing sedation and CNS depression, and it carries one of the highest anticholinergic burdens among over-the-counter (OTC) drugs [4]. The Anticholinergic Cognitive Burden (ACB) scale assigns diphenhydramine a score of 3 (the maximum), placing it alongside prescription agents like oxybutynin [5].

Anticholinergic Effects Relevant to Erectile Function

Anticholinergic drugs block muscarinic receptors. Penile erection depends partly on parasympathetic (cholinergic) nitric-oxide release from non-adrenergic non-cholinergic neurons; blocking this pathway may blunt the erectile response. More relevant to the interaction, however, is that autonomic reflex tachycardia, the heart's normal compensatory response to vasodilation and blood-pressure drop, depends on intact parasympathetic withdrawal. Diphenhydramine's anticholinergic action can impair that reflex, meaning blood pressure may drop further and recover more slowly when both drugs are active simultaneously [6].

CYP450 and Transporter Profile

Diphenhydramine is metabolized primarily by CYP2D6 (N-demethylation) and to a lesser degree by CYP1A2 and CYP3A4 [4]. Alprostadil is not a CYP substrate, inhibitor, or inducer; it undergoes local enzymatic oxidation independent of hepatic CYP pathways [2]. There is no pharmacokinetic (PK) drug-drug interaction between these two agents. The concern is entirely pharmacodynamic.

The Core Pharmacodynamic Interaction

The combination of a vasodilator (alprostadil) with an anticholinergic/CNS depressant (diphenhydramine) creates two overlapping problems.

Problem 1: Additive Hypotension

Alprostadil lowers systemic vascular resistance. Diphenhydramine, at standard adult doses of 25 to 50 mg, produces mild peripheral alpha-adrenergic blockade and direct cardiac depression that can reduce blood pressure independently [6]. When both mechanisms are active in the same time window, the hypotensive effect may be additive. Patients using MUSE, which has higher systemic absorption than Caverject, face a proportionally greater risk.

Problem 2: Impaired Reflex Tachycardia

Blood-pressure drops normally trigger baroreceptor-mediated reflex tachycardia. Diphenhydramine's anticholinergic activity raises resting heart rate but simultaneously blunts the parasympathetic component of the baroreflex arc, creating an incomplete and less effective compensatory response. A 2019 pharmacovigilance analysis in the British Journal of Clinical Pharmacology identified anticholinergic antihistamines as a drug class associated with orthostatic hypotension events when co-administered with vasodilatory agents [6].

Problem 3: CNS Depression and Fall Risk

Diphenhydramine at 50 mg produced significant psychomotor impairment in a randomized crossover trial (N=40), reducing reaction time by 24% compared to placebo [7]. Alprostadil's hypotension can cause dizziness. The combination raises the risk of syncope or falls, particularly in men who are older, hypertensive, or who take other antihypertensives concurrently.

HealthRX Clinical Risk Stratification for This Combination

| Patient Profile | Risk Level | Recommended Action | |---|---|---| | Age <55, normotensive, no other vasodilators | Low-moderate | Discuss with prescriber; avoid diphenhydramine on same day as alprostadil use | | Age 55-70, controlled hypertension on one agent | Moderate | Physician review required; consider loratadine or cetirizine instead | | Age >70, multiple antihypertensives, or prior syncope | High | Avoid combination; select non-anticholinergic antihistamine | | Any patient: MUSE form of alprostadil | Higher than Caverject | Same-day use not recommended without explicit physician clearance |

Severity Classification and DDI Database Context

Major drug interaction databases, including Drugs.com and Lexicomp, classify the alprostadil-diphenhydramine interaction as moderate severity. The interaction is flagged for the following reasons:

• Additive hypotensive pharmacodynamics
• Anticholinergic suppression of autonomic compensation
• Enhanced CNS depression and sedation increasing fall/syncope risk

"Moderate" in these databases means the combination is not absolutely contraindicated but warrants clinical judgment, possible dose reduction, and explicit patient counseling [8].

Alprostadil FDA Label Warnings Relevant to This Interaction

The FDA-approved Caverject prescribing information (revised 2014) states: "Patients on antihypertensive therapy may be at greater risk for hypotension following the administration of CAVERJECT. Therefore, hypotensive medications combined with CAVERJECT should be approached with caution." [1]

Diphenhydramine is not specifically named, but its blood-pressure-lowering and autonomic-blunting properties place it within the scope of this general warning. The MUSE label carries comparable language regarding hypotension risk and advises clinicians to review concomitant medications [3].

The FDA label for diphenhydramine (exemplified by the Benadryl OTC labeling) advises against concurrent use with other CNS depressants and notes that "marked drowsiness may occur" [9]. It does not reference vasodilators explicitly, which is why patient-initiated co-use without clinician input is a realistic and underappreciated risk.

Who Is Most at Risk?

Older Adults

Adults over 65 are disproportionately affected by both anticholinergic adverse effects and orthostatic hypotension. The American Geriatrics Society Beers Criteria explicitly lists diphenhydramine as a drug to avoid in older adults because of anticholinergic burden, fall risk, and cardiovascular effects [5]. Men in this age group who use alprostadil for erectile dysfunction, a common indication in older patients, face compound risk.

Men Taking Antihypertensive Drugs

Alprostadil's label warns that antihypertensive co-medication increases hypotension risk [1]. Adding diphenhydramine to an already risky combination produces a three-way pharmacodynamic interaction. A retrospective analysis of erectile-dysfunction drug-use patterns published in the Journal of Sexual Medicine found that 48% of men prescribed intracavernosal therapy were also on at least one antihypertensive agent [10].

Men with Cardiovascular Disease

Prostaglandin E1 analogs, including alprostadil, cause vasodilation that can precipitate angina in men with coronary artery disease if blood pressure drops sufficiently to reduce coronary perfusion pressure. Diphenhydramine's QTc-prolonging properties, documented in a 2015 study (N=205) that found 50 mg diphenhydramine extended the QTc interval by a mean of 11.8 ms [11], add a secondary cardiovascular concern in men with pre-existing QT prolongation or those on other QT-affecting drugs.

Monitoring Parameters

When a physician determines that both drugs must be used in proximity, the following monitoring is appropriate:

• Blood pressure and heart rate: Measure supine and standing BP 30 minutes after alprostadil administration. A drop of more than 20 mmHg systolic or 10 mmHg diastolic constitutes orthostatic hypotension by standard criteria [12].
• Priapism watch: Any erection lasting more than 4 hours requires emergency care. Diphenhydramine does not independently cause priapism, but the autonomic blunting it produces may theoretically prolong alprostadil-induced erections by slowing the sympathetic vasoconstriction that normally terminates the erectile response.
• CNS status: Sedation, confusion, or balance problems following the combination warrant discontinuation of diphenhydramine and a clinical review.
• QTc monitoring: In men with cardiac history or on other QT-prolonging agents, a baseline and post-dose ECG is reasonable if diphenhydramine is used regularly alongside alprostadil [11].

Safer Alternatives to Diphenhydramine

If antihistamine therapy is needed, second-generation agents are strongly preferred over diphenhydramine in men using alprostadil. The following options carry minimal or no anticholinergic burden and produce little to no CNS depression:

• Loratadine (Claritin) 10 mg daily: No significant anticholinergic activity; ACB score of 0; no clinically documented interaction with alprostadil [4].
• Cetirizine (Zyrtec) 10 mg daily: Minimal anticholinergic burden; mild sedation possible at higher doses but substantially less than diphenhydramine [4].
• Fexofenadine (Allegra) 180 mg daily: Non-sedating; no anticholinergic properties; does not cross the blood-brain barrier significantly [4].

Switching from diphenhydramine to one of these agents eliminates the pharmacodynamic anticholinergic/hypotension risk while still treating allergy symptoms. A 2021 Cochrane review of second-generation antihistamines confirmed that loratadine, cetirizine, and fexofenadine produce equivalent symptomatic relief to diphenhydramine for allergic rhinitis with markedly lower adverse-effect profiles [13].

Patient Counseling Points

Men prescribed alprostadil who ask about combining it with diphenhydramine should receive the following guidance:

Timing matters. Diphenhydramine's half-life is 4 to 8 hours, so "taking it the night before" does not eliminate overlap if alprostadil is used the following morning [9]. Allow at least 12 hours between diphenhydramine doses and alprostadil administration.

OTC does not mean risk-free. Diphenhydramine is available without a prescription, but that status does not confer safety when combined with prescription vasodilators.

Report symptoms immediately. Lightheadedness, dizziness, or fainting after using alprostadil while diphenhydramine is still active requires urgent evaluation. Lying flat and elevating the legs is first aid for hypotension while waiting for assessment.

Priapism is an emergency. Any erection lasting more than 4 hours demands emergency department evaluation, as irreversible erectile dysfunction can result from prolonged priapism [1].

Ask about alternatives. A prescriber or pharmacist can recommend a second-generation antihistamine that achieves the same therapeutic goal without the interaction risk.

Alprostadil Drug Interactions Beyond Diphenhydramine

For completeness, men using alprostadil should be aware that several other drug classes carry interaction risks:

• Antihypertensives (beta-blockers, calcium channel blockers, ACE inhibitors): Additive hypotension, explicitly warned in the FDA label [1].
• Other vasodilators (nitrates, PDE5 inhibitors like sildenafil): Potentially severe additive hypotension; PDE5 inhibitors are generally not combined with alprostadil.
• Anticoagulants (warfarin, heparin): Caverject injection carries a small bleeding risk at the injection site; anticoagulation increases this risk [1].
• Sympathomimetics (pseudoephedrine, phenylephrine): May reduce alprostadil's erectile efficacy by countering vasodilation.
• Vasoactive drugs used to treat priapism (phenylephrine intracavernosal): Used therapeutically to reverse prolonged alprostadil-induced priapism [1].